Lantern Pharma Inc (LTRN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.53-9.31%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LTRN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 8.7 | 11.5 | 16.1 | 11.9 | 8.6 | 7.6 | 2.2 |
| Operating Income | (15.5) | (18.0) | (22.2) | (17.9) | (14.4) | (12.6) | — |
| Net Income | |||||||
| Minority Interest | — | — | — | — | — | 12.4 | 5.9 |
| Net Income | (18.7) | (17.1) | (20.8) | (16.0) | (14.3) | (12.4) | (5.9) |
| Per Share | |||||||
| Basic EPS | (1.50) | (1.57) | (1.93) | (1.47) | (1.31) | (1.13) | — |
| Diluted EPS | (1.50) | (1.57) | (1.93) | (1.47) | (1.31) | — | — |
| Basic Weighted Avg Shares | 12.4 | 10.9 | 10.8 | 10.8 | 10.9 | 10.9 | — |
| Diluted Weighted Avg Shares | 12.4 | 10.9 | 10.8 | 10.8 | 10.9 | — | — |
| Supplemental | |||||||
| EBITDA | — | (18.0) | (22.2) | (17.9) | (14.4) | (12.6) | — |
| EBIT | (15.5) | (18.0) | (22.2) | (17.9) | (14.4) | (12.6) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.